PFS
RLAY icon

Prospera Financial Services’s Relay Therapeutics RLAY Stock Holding History

Prospera Financial Services’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-120
Closed -$2K – 1425
2022
Q2 		$2K Hold
120
– – ﹤0.01% 1563
2022
Q1 		$4K Buy
+120
New +$2.91K ﹤0.01% 2341

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prospera Financial Services's RLAY Position: Q3 2022 in Review

Prospera Financial Services sold out of Relay Therapeutics (RLAY) in Q3 2022, closing a stake of 120 shares — an estimated $2K sold.

Prospera Financial Services first reported a position in RLAY in Q1 2022 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 161 funds tracked by Wall St. Rank hold RLAY as of Q3 2022.

  • Prospera Financial Services reported no remaining Relay Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 120 Relay Therapeutics shares in Q3 2022, an estimated $2K.
  • Prospera Financial Services first reported a position in Relay Therapeutics in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's Relay Therapeutics position peaked at $4K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.